Savient's Gout Therapy Krystexxa Delayed At FDA.
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturing fixes should be straightforward - but the REMS submission could be tricky.
You may also be interested in...
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
Industry Wants More Transparency From Agency On REMS Determinations
SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions